CIPN

Asha Therapeutics Announces the Nomination of a Novel Intra-Molecular Glue Development Candidate ASHA-624 as a Disease Modifying Therapeutic for Amyotrophic Lateral Sclerosis

Retrieved on: 
Monday, April 1, 2024
Data Management, Other Health, Technology, Pharmaceutical, Oncology, General Health, Mental Health, Neurology, Clinical Trials, Other Technology, Biotechnology, Science, Software, Other Science, Research, Health, Conference, ALS, Disease, Patient, CNS, Amyotrophy, Asha, CIPN, Doctor of Philosophy, Tetraplegia, Safety, De novo, SARM1, Pharmaceutical industry

Asha Therapeutics (Asha) ( www.ashatherapeutics.com ), a life sciences company designing de novo disease modifying medicines for neurodegenerative diseases with high unmet medical need, announced today the nomination of a development candidate, ASHA-624 targeting SARM1 as a potential disease modifying therapy for Amyotrophic Lateral Sclerosis (ALS) with additional indications in Chemotherapy-Induced Peripheral Neuropathy (CIPN), Glaucoma, and traumatic brain and spinal cord injuries.

Key Points: 
  • Asha Therapeutics (Asha) ( www.ashatherapeutics.com ), a life sciences company designing de novo disease modifying medicines for neurodegenerative diseases with high unmet medical need, announced today the nomination of a development candidate, ASHA-624 targeting SARM1 as a potential disease modifying therapy for Amyotrophic Lateral Sclerosis (ALS) with additional indications in Chemotherapy-Induced Peripheral Neuropathy (CIPN), Glaucoma, and traumatic brain and spinal cord injuries.
  • Dr. Michael Gold, MD, MS, a member of Asha’s Scientific Advisory Board noted, “SARM-1 is a well-validated therapeutic target that could yield novel therapies for patients suffering from a range of both central and peripheral nervous disorders.
  • ASHA-624 prevents the activation of SARM-1 using a completely novel approach that has the potential to deliver a therapy with robust clinical efficacy and few, if any, off-target side effects.
  • We are committed through our work to the transformation of patient outcomes, and believe ASHA-624 is a significant step forward towards achieving that goal,” commented Dr. Heckmann, PhD.

Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer

Retrieved on: 
Monday, March 4, 2024
Montreal Cognitive Assessment, CIPN, Prostate cancer, Chemotherapy-induced peripheral neuropathy, MBA, Therapy, Internal medicine, Drug, Novartis, Pharmacotherapy, Oncology, IND, CICI, Pharmaceutical industry

NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced that it has appointed Ron Weitzman, M.D., as interim Chief Medical Officer, replacing Arthur DeCillis, M.D., who is joining Osmol’s Scientific Advisory Board.

Key Points: 
  • NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Osmol Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing preventative treatments for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), today announced that it has appointed Ron Weitzman, M.D., as interim Chief Medical Officer, replacing Arthur DeCillis, M.D., who is joining Osmol’s Scientific Advisory Board.
  • “We are pleased to welcome Ron, with his significant oncology drug development expertise, to the Osmol team,” said Bob Linke, MBA, President and CEO of Osmol Therapeutics.
  • Ron Weitzman, M.D., has held leadership roles at various global biopharmaceutical companies, including Tango Therapeutics, Exelixis, Genentech and Novartis.
  • Most recently he served as Chief Medical Officer at Tango Therapeutics, where he oversaw development of multiple oncology drugs, including three Investigational New Drug (IND) applications, while leading the clinical and clinical operations teams.

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

Retrieved on: 
Thursday, February 22, 2024
CIPN, PIN, CMS, Pressure, Absorption, Telephone, FDA, Telehealth, Growth, Peripheral neuropathy, Common, Risk, COVID-19, Medicare, Fibromyalgia, DSM-IV codes, CDC, Long, Prescription, Environment, Baylor University, Pharmaceutical industry

WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.

Key Points: 
  • WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.
  • "Quell® Fibromyalgia growth accelerated in Q4 2023 reflecting the addition in Q3 2023 of two field business development managers and optimized clinical messaging.
  • In the successive quarters of Q4 2023 versus Q3 2023, all key operating metrics showed substantial growth.
  • The Q4 2023 net loss was $1.6 million ($1.43 per share) versus a net loss of $0.7 million ($0.73 per share) in Q4 2022.

Bexion Pharmaceuticals, Inc. Appoints Dr. Tariq Arshad as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, CIPN, MD, ASCO, Strategic planning, SITC, Clinical research, Chemotherapy-induced peripheral neuropathy, AACR, MBA, Society, Immunology, Patient, Immunotherapy, Head, Medical device

COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.

Key Points: 
  • COVINGTON, Ky., Feb. 28, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Tariq Arshad, MD, MBA as Chief Medical Officer.
  • Dr. Arshad is an oncologist with more than 25 years of experience and a successful track record of strategic planning, clinical development, and commercialization.
  • "We are thrilled to appoint Dr. Arshad as Bexion's Chief Medical Officer," said Scott Shively, Bexion's Chief Executive Officer.
  • Dr. Arshad previously led medical strategies for blockbuster biologic therapies approved for clinical use in major immunology indications and other groundbreaking therapies as Head of Medical Affairs for Immunology at Sanofi, and he served as Chief Medical Officer and Head of Clinical Research at Humanigen, developing novel immune-oncology therapies.

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

Retrieved on: 
Tuesday, January 23, 2024
Senior, Patient, Diabetic neuropathy, Oxaliplatin, Research, CIPN, Peripheral neuropathy, Chemotherapy-induced peripheral neuropathy, Discovery, Cancer, The Journal of Pain, IND, Food, Neuropathic pain, FDA, Pain, Doctor of Philosophy, FABP5, Fatty acid, Pharmaceutical industry

The research article, titled “ Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy ,” highlights Artelo’s pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in a series of separate studies.

Key Points: 
  • The research article, titled “ Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy ,” highlights Artelo’s pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in a series of separate studies.
  • ART26.12 is a Fatty Acid Binding Protein 5 (FABP5) inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy (CIPN), a type of neuropathic pain caused by chemotherapy as well as non-chemotherapy cancer treatments such as immunomodulating drugs.
  • Artelo has conducted multiple pre-clinical studies in painful neuropathies, including diabetic neuropathy, paclitaxel-induced peripheral neuropathy, and OIPN, the latter two of which has no FDA-approved treatment.
  • The Company previously reported a positive pre-IND (investigational new drug) meeting with the Food and Drug Administration (FDA) and anticipates filing the IND for ART26.12 in the first half of 2024.

Vision Sensing Acquisition Corp. Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd

Retrieved on: 
Tuesday, January 16, 2024
Pub, State, Research, VSAC, CIPN, Biotechnology, Stroke, Mergers and acquisitions, Quality of life, PD, Alzheimer's disease, Acquisition, Safety, Drug development, Neuropathic pain, Peripheral neuropathy, DPN, Pharmaceutical industry

Subject to the terms and conditions set forth in the Merger Agreement, upon the closing of the transactions, the combined company will be listed on NASDAQ under a new ticker symbol.

Key Points: 
  • Subject to the terms and conditions set forth in the Merger Agreement, upon the closing of the transactions, the combined company will be listed on NASDAQ under a new ticker symbol.
  • Mediforum, a leading biotechnology firm in Korea, stands as a global pioneer in biotechnology, dedicated to advancing biomedical sciences through innovative and ethical practices.
  • With a diverse portfolio ranging from anti-dementia medications to health functional foods, Mediforum is at the forefront of biomedical innovation.
  • Both the surviving corporations of Initial Merger and SPAC Merger will be direct wholly owned subsidiaries of PubCo.

Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2024

Retrieved on: 
Tuesday, January 16, 2024
Patient, CIPN, ASCO, Chemotherapy-induced peripheral neuropathy, Bevacizumab, Society, Safety, FOLFOX, Cancer, Management

COVINGTON, Ky., Jan. 16, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA.

Key Points: 
  • COVINGTON, Ky., Jan. 16, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA.
  • Poster details are included below.
  • "We are excited to present our ongoing trial of BXQ-350 in mCRC during the 2024 ASCO GI Symposium" said Scott Shively, CEO and President of Bexion Pharmaceuticals.
  • "BXQ-350 in combination with FOLFOX and bevacizumab offers a unique opportunity to improve outcomes for 1st line patients with mCRC.

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

Retrieved on: 
Monday, January 8, 2024
Food, IND, FDA, Pain, Cancer, Chemotherapy-induced peripheral neuropathy, CIPN, Worldwide, Diabetic neuropathy, Patient, Safety, FABP5, Therapy, Pharmaceutical industry

“We look forward to working with Worldwide once we obtain approval from the FDA to advance ART16.12 into Phase 1 clinical development,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.

Key Points: 
  • “We look forward to working with Worldwide once we obtain approval from the FDA to advance ART16.12 into Phase 1 clinical development,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • “With Worldwide’s extensive experience in the neurology space and successful track record of assisting companies progress through trials, we believe we are well positioned to leverage ART26.12’s positive profile observed in multiple animal models of painful neuropathies to progress to human studies.”
    “We are excited to partner with the Artelo Biosciences team on their important advancement with ART26.12,” stated Peter Benton, President and Chief Executive Officer of Worldwide Clinical Trials.
  • Artelo has conducted five pre-clinical studies in painful neuropathies, including diabetic neuropathy and chemotherapy-induced peripheral neuropathy, the latter of which has no FDA-approved treatment.
  • The Company previously reported a positive pre-IND (investigational new drug) meeting with the Food and Drug Administration and anticipates filing the IND for ART26.12 in the first half of this year.

Bexion Pharmaceuticals, Inc. to Present at Biotech Showcase 2024

Retrieved on: 
Friday, January 5, 2024
Chemotherapy-induced peripheral neuropathy, CIPN, Conference, Biotechnology

COVINGTON, Ky., Jan. 5, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan 42nd Annual Healthcare Conference week. Biotech Showcase 2024 will be held in-person, from January 8-10, 2024, in San Francisco, CA.

Key Points: 
  • COVINGTON, Ky., Jan. 5, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan 42nd Annual Healthcare Conference week.
  • Biotech Showcase 2024 will be held in-person, from January 8-10, 2024, in San Francisco, CA.
  • Scott Shively, CEO and President of Bexion Pharmaceuticals, and Joyce LaViscount, Chief Financial Officer of Bexion Pharmaceuticals, will attend the conference.
  • Additionally, the Bexion management team will host one-on-one meetings with potential investors in San Francisco from January 8-11, 2024.

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

Retrieved on: 
Tuesday, December 5, 2023
Peripheral neuropathy, Quality of life, The Journal of Pain, TENS, ASCO, FDA, Clinical trial, CIPN, NIH, Patient, Safety, RCT, Journal, Skin, Pharmaceutical industry

The study was a phase 2, multi-site, double blinded, randomized, sham-controlled trial.

Key Points: 
  • The study was a phase 2, multi-site, double blinded, randomized, sham-controlled trial.
  • A total of 142 subjects with CIPN were randomized to an active or sham Quell device for 6-weeks.
  • Duloxetine is the only treatment recommended for painful chronic CIPN in the current American Society of Clinical Oncology (ASCO) guidelines.
  • The use of Quell for chemotherapy induced peripheral neuropathy is investigational and has not been cleared or approved by the FDA.